Seres Therapeutics, Inc. (NASDAQ:MCRB) Short Interest Update

Seres Therapeutics, Inc. (NASDAQ:MCRB) saw a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 799,000 shares, a growth of 30.9% from the April 30th total of 610,400 shares. Approximately 12.4% of the shares of the company are sold short. Based on an average daily volume of 85,200 shares, the short-interest ratio is currently 9.4 days.

Institutional Trading of Seres Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Millennium Management LLC raised its stake in Seres Therapeutics by 77.2% during the fourth quarter. Millennium Management LLC now owns 1,810,719 shares of the biotechnology company’s stock worth $1,505,000 after buying an additional 788,762 shares during the last quarter. Vontobel Holding Ltd. grew its stake in Seres Therapeutics by 137.6% in the 4th quarter. Vontobel Holding Ltd. now owns 938,295 shares of the biotechnology company’s stock valued at $780,000 after buying an additional 543,469 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Seres Therapeutics by 8.8% in the fourth quarter. Geode Capital Management LLC now owns 1,510,432 shares of the biotechnology company’s stock worth $1,256,000 after purchasing an additional 121,793 shares during the period. Charles Schwab Investment Management Inc. raised its position in Seres Therapeutics by 15.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 865,825 shares of the biotechnology company’s stock valued at $720,000 after purchasing an additional 117,107 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in Seres Therapeutics by 193.2% during the 1st quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 89,995 shares during the last quarter. Institutional investors and hedge funds own 59.34% of the company’s stock.

Seres Therapeutics Stock Performance

Shares of MCRB opened at $7.10 on Wednesday. Seres Therapeutics has a twelve month low of $6.53 and a twelve month high of $30.60. The firm’s 50 day moving average price is $9.26 and its 200 day moving average price is $13.84. The firm has a market cap of $61.95 million, a PE ratio of -31.69 and a beta of 2.89.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported ($2.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($1.57). On average, sell-side analysts anticipate that Seres Therapeutics will post -0.38 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Chardan Capital restated a “neutral” rating and issued a $6.00 price target (up previously from $1.25) on shares of Seres Therapeutics in a research report on Thursday, May 8th. Wall Street Zen raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, May 9th. Finally, The Goldman Sachs Group cut their target price on shares of Seres Therapeutics from $20.00 to $15.00 and set a “sell” rating on the stock in a research note on Friday, March 14th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $73.67.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.